 |
인쇄하기
취소
|
Peluvi fares well in analgesic/anti-inflammatory market
Daewon Pharm is enjoying brisk sales of its new nonsteroidal anti-inflammatory drug (NSAID), Peluvi (felubiprofen).
Sales of Daewon’s felubiprofen reached over 2.0 billion won since its release in October 2008, making it one of the top-selling drugs in the country.
Felubiprofen is Korea’s 12th homegrown analgesic/anti-inflammatory medicine and was approved by the Korea Food and Drug Admi...
Sales of Daewon’s felubiprofen reached over 2.0 billion won since its release in October 2008, making it one of the top-selling drugs in the country.
Felubiprofen is Korea’s 12th homegrown analgesic/anti-inflammatory medicine and was approved by the Korea Food and Drug Admi...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.